Attorneys general ask HHS to punish 340B program bilkers — but pharma claims it's fighting 'waste and abuse'

Kyle Blankenship

Imagined as a benefit for low-income patients, the government’s 340B scheme requires participating drugmakers to sell their drugs at significant discounts to play ball in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Attorneys general ask HHS to punish 340B program bilkers — but pharma claims it's fighting 'waste and abuse'

Kyle Blankenship

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

At­tor­neys gen­er­al ask HHS to pun­ish 340B pro­gram bilk­ers — but phar­ma claims it's fight­ing 'waste and abuse'

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Attorneys general ask HHS to punish 340B program bilkers — but pharma claims it's fighting 'waste and abuse'